Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a ...

MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...

The White House announced it has signed nine new agreements with pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi ...

High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...

Q. My doctor prescribed rosuvastatin for high cholesterol. After taking it for six to nine months, I noticed that my cognitive function had slipped. I would not be able to find the word I was looking ...

President Donald Trump’s deals with pharmaceutical companies are likely to have only a limited impact on Americans’ drug spending, experts say. Since Sept. 30, the Trump administration has struck ...

TrumpRx is set to launch soon. President Donald Trump has been pressuring drug companies to lower prices. Americans currently pay about three times more for prescription medicine than patients in ...

Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert ...

Leqvio (inclisiran) is a prescription drug used to help treat certain types of high cholesterol. Leqvio comes in a prefilled syringe for injection under the skin. Leqvio contains the active drug ...

Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year, supported by strong financial ...